MAO-B inhibitors

MAO-B inhibitors

Inhibitors of the enzyme monoamine oxidase B. MAO-B helps break down dopamine; inhibiting it prolongs the action of dopamine in the brain. Selegiline is an MAO-B inhibitor.
Mentioned in: Parkinson Disease
References in periodicals archive ?
Based on drug class, the market has been further segmented into Levodopa combination, dopamine agonists, MAO-B Inhibitors, COMT Inhibitors, and others.
Research shows that both dopamine agonists and MAO-B inhibitors are less effective than carbidopa/levodopa at quelling the motor symptoms associated with PD.
Thus, considering dopamine agonists and MAO-B inhibitors as initial therapy in patients ages <60 years may be helpful, since they typically will be taking medication longer.
Kupeli et al., "A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics," Bioorganic and Medicinal Chemistry, vol.
Bolasco, "Selective MAO-B inhibitors: A lesson from natural products," Molecular Diversity, vol.
Results show that the tested substances are powerful selective MAO-B inhibitors, yet with the reversible type of inhibition typical of natural substances and plausibly devoid of any significant side effects.
A number of MAO-B inhibitors used in the clinical setting for treating Parkinson's disease have unwanted side effects.
MAO-B inhibitors thus help improve the symptomatic motor effects of PD.
Agents such as the dopamine agonists, COMT inhibitors and MAO-B inhibitors can assist in addressing these.
Depression in patients with dementia can be treated with selected tricyclics, MAO-B inhibitors, and selective serotonin reuptake inhibitor medications.
MAO-B inhibitors: Minimally effective with troubling side effects
Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 29: 279-292